Aclaris Therapeutics announces positive top-line results from phase 2a clinical trial of ATI-2138: Wayne, Pennsylvania Friday, August 1, 2025, 14:00 Hrs [IST] Aclaris Therapeutics ...

Mirikizumab shows early and sustained efficacy in reducing bowel urgency and achieving remission in patients with moderate-to ...

Diagnostic indicators are identified for confirming chronic neuropathic ocular pain (NOP) for patients experiencing chronic dry eye (DE) after laser-assisted in situ keratomileusis (LASIK).

Itching is often the most debilitating cutaneous symptom of CKD and ESRD. Experts recommend a stepwise treatment approach ...

Investing.com -- Aclaris Therapeutics Inc (NASDAQ: ACRS) stock surged 20% in after-hours trading following the announcement of positive top-line results from its Phase 2a trial of ATI-2138 in patients ...

Opioid-limiting pain management education and counseling reduce opioid consumption with no increase in postoperative pain ...

A real-world study on JAK inhibitors in atopic dermatitis reveals that while body weight has minimal impact on short-term ...

The hidradenitis suppurativa (HS) market across the seven major pharmaceutical markets (7MM: US, France, Germany, Italy, ...

Compared with standard care, online dialectical behavioral therapy improved emotion regulation and psychologic outcomes among adults with chronic pain.

Uremic pruritus of chronic kidney disease is prevalent and challenging to treat. Research provides insights into potentially effective therapies.

Pain and opioid use were reduced in patients with advanced knee OA following ultrasound-guided chemical neurolysis of 4 genicular nerves.

Patients with moderate to severe atopic dermatitis experienced a 71% decrease in Eczema Area and Severity Index scores from baseline through 16 weeks with APG777, an anti-IL-13 antibody from Apogee ...